Drug-induced lupus after treatment with infliximab in rheumatoid arthritis

被引:40
作者
Benucci, M
Gobbi, FL
Fossi, F
Manfredi, M
Del Rosso, A
机构
[1] Nuovo Osped S Giovanni Dio, Rheumatol Sect, I-50143 Florence, Italy
[2] Nuovo Osped S Giovanni Dio, Immunol Sect, I-50143 Florence, Italy
[3] Univ Florence, Rheumatol Sect, Dept Med, Florence, Italy
关键词
drug-induced lupus; infliximab; anti-TNF alpha therapy; rheumatoid arthritis;
D O I
10.1097/01.rhu.0000152148.55133.ba
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report a case of a 45-year-old man with an 8-month history of rheumatoid arthritis, who was treated with hydroxychloroquine 400 mg per day and 15 mg intramuscular methotrexate per week without reaching a good control of the disease. The patient was successfully treated with 3 mg/kg infliximab for 20 weeks. Before the last infusion, drug-induced lupus (DIL) was diagnosed based on the clinical features of fever > 37.5degreesC, recurrence of active synovitis, myalgia, erythematosus rash, pericardial and pleural effusion, and of some laboratory findings (antinuclear antibodies 1: 160 and anti double-strand DNA positive by DNA recombinant plasmid assay dsDNA). After infliximab discontinuation and the beginning of therapy with methylprednisolone, lupus symptoms resolved within 6 weeks. A new rheumatoid arthritis flare, occurring after 8 weeks, was controlled by methotrexate plus leflunomide. We also review the development of antinuclear and antidouble-strand DNA antibodies and drug-induced lupus in patients treated with anti-TNFalpha agents (infliximab, etanercept, and adalimumab).
引用
收藏
页码:47 / 49
页数:3
相关论文
共 22 条
[1]   Infliximab-induced systemic lupus erythematosus [J].
Ali, Y ;
Shah, S .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (07) :625-626
[2]   New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis [J].
Cairns, AP ;
Duncan, MKJ ;
Hinder, AE ;
Taggart, AJ .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (11) :1031-1032
[3]   Reduced expression of CD44 on monocytes and neutrophils in systemic lupus erythematosus: relations with apoptotic neutrophils and disease activity [J].
Cairns, AP ;
Crockard, AD ;
McConnell, JR ;
Courtney, PA ;
Bell, AL .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (10) :950-955
[4]  
Charles PJ, 2000, ARTHRITIS RHEUM, V43, P2383, DOI 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO
[5]  
2-D
[6]   Adverse reactions to TNF-α inhibitors in rheumatoid arthritis [J].
Day, R .
LANCET, 2002, 359 (9306) :540-541
[7]  
ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362
[8]   Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections [J].
Ferraccioli, G ;
Mecchia, F ;
Di Poi, E ;
Fabris, M .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (04) :358-361
[9]   Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes [J].
Genovese, MC ;
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Cannon, GW ;
Spencer-Green, G ;
Finck, BK .
ARTHRITIS AND RHEUMATISM, 2002, 46 (06) :1443-1450
[10]  
Jonsdottir T, 2002, ARTHRITIS RHEUM-US, V46, pS573